How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

21,632 results for

Breast Cancer Diagnosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale (...) , particularly when compared with modifications of digital mammography that involve spot compression and magnified and angled views. Key Questions: Does digital breast tomosynthesis (DBT) provide a more accurate diagnosis than conventional mammography in women with symptoms or suspicious breast lesions? Does DBT reduce the recall and biopsy rates and the rates of breast cancer morbidity and mortality in asymptomatic women who undergo routine screening with this test? Does information obtained with DBT

2017 Health Technology Assessment (HTA) Database.

2. Modifiable patient-related barriers and their association with breast cancer detection practices among Ugandan women without a diagnosis of breast cancer. (PubMed)

Modifiable patient-related barriers and their association with breast cancer detection practices among Ugandan women without a diagnosis of breast cancer. Most women with breast cancer in sub-Saharan Africa (SSA) are diagnosed with late-staged disease. The current study assesses patient-related barriers among women from a general SSA population to better understand how patient-related barriers contribute to diagnostic delays. Using convenience-based sampling, 401 Ugandan women without breast (...) cancer were surveyed to determine how prior participation in cancer detection practices correlate with patient-related barriers to prompt diagnosis. In a predominantly poor (76%) and rural population (75%), the median age of the participants was 38. Of the women surveyed, 155 (46%) had prior exposure to breast cancer education, 92 (27%) performed breast self-examination (BSE) and 68 (20%) had undergone a recent clinical breast examination (CBE), breast ultrasound or breast biopsy. The most commonly

Full Text available with Trip Pro

2019 PLoS ONE

3. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast (PubMed)

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast (...) and statements which were modified and graded in a structured consensus procedure. Recommendations Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women

Full Text available with Trip Pro

2018 Geburtshilfe Und Frauenheilkunde

4. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Digital breast tomosynthesis for breast cancer diagnosis and screening (...) . Lansdale: HAYES, Inc.. Directory Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Humans; Mammography; Public Health; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

2015 Health Technology Assessment (HTA) Database.

5. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. (PubMed)

Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. To examine whether obesity/overweight is a risk predictor for breast cancer recurrence and death by menopausal status in a retrospective study.We performed a retrospective analysis of 1017 breast cancer patients treated in our hospital from January 2004 to December 2012. Three groups were divided according to body mass index (BMI) when breast cancer diagnosis: normal weight, BMI (...)  < 25.0 kg/m; overweight, 25.0≤BMI < 30.0 kg/m; and obesity, BMI≥30.0 kg/m. The clinicopathological characteristics and clinical outcomes of patients within 5 years following breast cancer diagnosed were analyzed. Subgroup analyses of BMI on breast cancer prognosis were analyzed according to the menopausal status when breast cancer diagnosis. The Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Overweight and obesity groups were associated

Full Text available with Trip Pro

2018 Medicine

6. Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study (PubMed)

Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study The diagnosis of cancer can motivate patients to change their dietary habits. Evidence on changes in dietary intake before and after breast cancer diagnosis in Chinese women has been limited.In an ongoing prospective cohort study which involved 1,462 Chinese women with early-stage breast cancer, validated food frequency questionnaire was used to assess prediagnostic dietary (...) intake (using questionnaire to recall dietary intake before diagnosis, which completed at baseline, ie, 0-12 months after diagnosis) and postdiagnostic dietary intake at 18-month and 36-month follow-ups after diagnosis. This study quantitatively compared dietary intake across three time points before and after breast cancer diagnosis.Breast cancer patients significantly and continuously increased vegetables and fruits consumption, from 4.54 servings/day at prediagnosis to 5.19 and 5.59 servings/day

Full Text available with Trip Pro

2018 Cancer management and research

7. APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis. (PubMed)

APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis. The aim of this study was to evaluate the clinical efficacy of APC gene promoter methylation in serum as a biomarker for breast cancer (BC) diagnosis.Two reviewers systematically searched online resources to identify the publications relevant to APC gene promoter methylation and BC. The data of true positive, false positive, false negative, and true negative were extracted from each (...) ), 4.58 (95% CI 1.85-11.37) and 0.80, respectively. A Deeks' funnel plot and Egger's line regression test (t = 1.43, P = 0.18) indicated no publication bias was present.Because of low sensitivity, APC gene promoter methylation in serum was not suitable for BC screening. However, as specificity was very high, detection of serum APC gene promoter methylation could be used as tool to confirm BC.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

8. Change in longitudinal trends in sleep quality and duration following breast cancer diagnosis: results from the Women’s Health Initiative (PubMed)

Change in longitudinal trends in sleep quality and duration following breast cancer diagnosis: results from the Women’s Health Initiative Breast cancer survivors frequently report sleep problems, but little research has studied sleep patterns longitudinally. We examined trends in sleep quality and duration up to 15 years before and 20 years after a diagnosis of breast cancer, over time among postmenopausal women participating in the Women's Health Initiative (WHI). We included 12,098 (...) participants who developed invasive breast cancer after study enrollment. A linear mixed-effects model was used to determine whether the time trend in sleep quality, as measured by the WHI Insomnia Rating Scale (WHIIRS), a measure of perceived insomnia symptoms from the past 4 weeks, changed following a cancer diagnosis. To examine sleep duration, we fit a logistic regression model with random effects for both short (<6 h) and long (≥9 h) sleep. In addition, we studied the association between depressive

Full Text available with Trip Pro

2018 NPJ breast cancer

9. Reclassification of breast cancer: Towards improved diagnosis and outcome. (PubMed)

Reclassification of breast cancer: Towards improved diagnosis and outcome. The subtyping of breast cancer based on features of tumour biology such as hormonal receptor and HER2 status has led to increasingly patient-specific treatment and thus improved outcomes. However, such subgroups may not be sufficiently informed to best predict outcome and/or treatment response. The incorporation of multi-modal data may identify unexpected and actionable subgroups to enhance disease understanding (...) and improve outcomes.This retrospective cross-sectional study used the cancer registry Surveillance, Epidemiology and End Results (SEER), which represents 28% of the U.S. population. We included adult female patients diagnosed with breast cancer in 2010. Latent class analysis (LCA), a data-driven technique, was used to identify clinically homogeneous subgroups ("endophenotypes") of breast cancer from receptor status (hormonal receptor and HER2), clinical, and demographic data and each subgroup

Full Text available with Trip Pro

2019 PLoS ONE

10. Prostate cancer: diagnosis and management

bicalutamide monotherapy (longer than 6 months), offer prophylactic radiotherapy to both breast buds within the first month of treatment. Use a single fraction of 8 Gy using orthovoltage, or electron beam radiotherapy. [2008] [2008] 1.4.17 If radiotherapy does not prevent gynaecomastia, consider weekly tamoxifen [5] . [2008] [2008] F Fatigue atigue 1.4.18 T ell people who are starting androgen deprivation therapy that fatigue is a Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights (...) Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

11. Breast surgery for metastatic breast cancer. (PubMed)

2016. We also searched ClinicalTrials.gov (22 February 2016) and the WHO International Clinical Trials Registry Platform (24 February 2016). We conducted an additional search in the American Society of Clinical Oncology (ASCO) conference proceedings in July 2016 that included reference checking, citation searching, and contacting study authors to identify additional studies.The inclusion criteria were randomised controlled trials of women with metastatic breast cancer at initial diagnosis comparing (...) Breast surgery for metastatic breast cancer. Metastatic breast cancer is not a curable disease, but women with metastatic disease are living longer. Surgery to remove the primary tumour is associated with an increased survival in other types of metastatic cancer. Breast surgery is not standard treatment for metastatic disease, however several recent retrospective studies have suggested that breast surgery could increase the women's survival. These studies have methodological limitations

2018 Cochrane

12. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale: HAYES, Inc (...) .. Directory Publication. 2014 Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Early Detection of Cancer; Females; Imaging, Three-Dimensional; Mammography; Mass Screening; Radiographic Image Enhancement; Safety; Sensitivity and Specificity; Tomography, X-Ray Computed

2014 Health Technology Assessment (HTA) Database.

13. Use of Digital Breast Tomosynthesis with Mammography for Breast Cancer Screening or Diagnosis

Use of Digital Breast Tomosynthesis with Mammography for Breast Cancer Screening or Diagnosis Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) BlueCross BlueShield Association. Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 28(6). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasmss; Imaging, Three-Dimensional; Mammography; Mass Screening Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

2014 Health Technology Assessment (HTA) Database.

14. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis. (PubMed)

Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis. This study aimed to systematically review and to meta-analyse the accuracy of digital breast tomosynthesis (DBT) versus digital mammography (DM) in women with mammographically dense breasts in screening and diagnosis.Two independent reviewers identified screening or diagnostic studies reporting at least one of four outcomes (cancer detection rate-CDR (...) , recall rate, sensitivity and specificity) for DBT and DM in women with mammographically dense breasts. Study quality was assessed using QUADAS-2. Meta-analysis of CDR and recall rate used a random effects model. Summary ROC curve summarized sensitivity and specificity.Sixteen studies were included (five diagnostic; eleven screening). In diagnosis, DBT increased sensitivity (84%-90%) versus DM alone (69%-86%) but not specificity. DBT improved CDR versus DM alone (RR: 1.16, 95% CI 1.02-1.31

Full Text available with Trip Pro

2018 BMC Cancer

15. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

For referral decisions, attempts should be made to gather as accurate information as possible on: age of diagnosis of any cancer in relatives site of tumours multiple cancers (including bilateral disease) Jewish ancestry [1] . [2004] [2004] F Family history-taking in secondary car amily history-taking in secondary care e 1.1.10 A family history should be taken when a person with no personal history of breast cancer presents with breast symptoms or has concerns about relatives with breast cancer. [2004 (...) with a family history of breast cancer (CG164) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 20 of 48Genetic testing for Genetic testing for BR BRCA1 CA1, , BR BRCA2 CA2 and and TP53 TP53 mutations within 4 mutations within 4 weeks of diagnosis of weeks of diagnosis of breast cancer breast cancer 1.5.14 Offer people eligible for referral to a specialist genetic clinic a choice of accessing genetic testing during initial

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Foundation and methodologies in computer-aided diagnosis systems for breast cancer detection (PubMed)

Foundation and methodologies in computer-aided diagnosis systems for breast cancer detection Breast cancer is the most prevalent cancer that affects women all over the world. Early detection and treatment of breast cancer could decline the mortality rate. Some issues such as technical reasons, which related to imaging quality and human error, increase misdiagnosis of breast cancer by radiologists. Computer-aided detection systems (CADs) are developed to overcome these restrictions and have been (...) studied in many imaging modalities for breast cancer detection in recent years. The CAD systems improve radiologists' performance in finding and discriminating between the normal and abnormal tissues. These procedures are performed only as a double reader but the absolute decisions are still made by the radiologist. In this study, the recent CAD systems for breast cancer detection on different modalities such as mammography, ultrasound, MRI, and biopsy histopathological images are introduced

Full Text available with Trip Pro

2017 EXCLI journal

17. The Effects of Training on Knowledge and Beliefs About Breast Cancer and Early Diagnosis Methods Among Women (PubMed)

The Effects of Training on Knowledge and Beliefs About Breast Cancer and Early Diagnosis Methods Among Women Breast cancer (BC) is the most common female malignancy in the world and Turkey. Its prevalence and mortality are surprisingly increasing at a rapid rate. The objective of this study was to determine the effectiveness of training sessions on women's knowledge of relevant risk factors of BC and screening methods, screening behaviors and health beliefs among of healthy women in Turkey.In (...) of the women was 39.44 (SD=1.06) years. The mean total knowledge score increased significantly (p<.001) from 9.05 in the pre-test to 16.53 in the post-test. The results showed that both mean knowledge scores and CHBMS subscales scores of the women were increased significantly (p<.001) from the pre-test to the post-test. In multiple linear regression analysis, BC screening knowledge of women with susceptibility, benefit, self-efficacy and health motivation subscales of CHBMS, breast self-examination (BSE

Full Text available with Trip Pro

2017 European journal of breast health

18. Evaluation on the Practice and Behaviour of Women Applied for Gynecology Outpatient Clinics About Screening Methods for Early Diagnosis of Breast Cancer (PubMed)

Evaluation on the Practice and Behaviour of Women Applied for Gynecology Outpatient Clinics About Screening Methods for Early Diagnosis of Breast Cancer Breast self-examination (BSE), clinical breast exam (CBE), mammography and ultrasound imaging (UI) are screening methods used for early diagnosis of breast cancer (BC). The purpose of this study is to put forth the utilization frequency of these screening methods among women presenting to the gynecology outpatient clinics and the relation (...) of these data with the socio-demographic characteristics of the women.A survey was conducted among 429 women (age, 16-80 years) who were admitted to the gynecology outpatient clinics. The survey inquired about the rate and frequency of the performance of BSE, CBE, mammography and UI; personal and family history of breast cancer and social-demographic characteristics of the women.The mean age was 40.08 (SD: 3.67). More than half of the women above 40 years of age (59.7 %) had never undergone mammography

Full Text available with Trip Pro

2017 European journal of breast health

19. Impact of full field digital mammography (FFDM) diagnosis for patients with breast cancer (BC): a systematic review protocol of clinical studies

Impact of full field digital mammography (FFDM) diagnosis for patients with breast cancer (BC): a systematic review protocol of clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

20. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer TITLE: Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy and Guidelines DATE: 23 December 2014 RESEARCH QUESTIONS 1. What is the clinical effectiveness of digital tomosynthesis compared with mammography for breast cancer screening? 2. What is the clinical effectiveness of digital tomosynthesis as an adjunct to mammography compared with mammography alone for breast cancer screening? 3 (...) . What is the clinical effectiveness of digital tomosynthesis compared with mammography for breast cancer diagnosis? 4. What is the clinical effectiveness of digital tomosynthesis as an adjunct to mammography compared with mammography alone for breast cancer diagnosis? 5. What are the evidence-based guidelines regarding the use of digital tomosynthesis for breast cancer screening and diagnosis? KEY FINDINGS Two systematic reviews, 17 non-randomized studies, and one evidence-based guideline were

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>